$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Natera Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Sales Guidance Above Estimates.
Natera GAAP EPS of -$0.50 Beats by $0.12, Revenue of $501.8M Beats by $55.13M
FDA to Speed up AI Rollout to Accelerate Drug Reviews
Corteva Analyst Ratings
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
Natera To Present Multiple Datasets In Breast Cancer Together With Collaborators At 2025 ESMO Breast Cancer Annual Congress In Munich
Here Are the Major Earnings After the Close Today
Merck Boosts U.S. Investments With $895M Expansion in Kansas Site
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought
Trump Planning on Executive Order to Further Cut Medicare Drug Prices - Report
Lilly Benefits as Judge Upholds FDA Removing Zepbound From Shortages List
Vertex Pharma Extends Selloff as Wolfe Downgrades After Q1 Miss
Gilead to Invest About $32B in U.S. Manufacturing Through 2030
S&P 500's Five Most Overbought and Oversold Stocks
SA Analyst Upgrades: TSLA, MSFT, AMD, PLTR, VRTX, ONON, CB
Preview: Natera's Earnings
Price Over Earnings Overview: Regeneron Pharmaceuticals
Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook